AbbVie Inc (ABBV)
AbbVie: Wins Accumulating While We Wait For Next BD Steps
AbbVie is outperforming expectations with strong commercial results, pipeline progress, and the legal win that secured Rinvoq's long-term market exclusivity. ABBV has raised the full-year revenue guidance by $1.5 billion since the start of the year, and I am raising my estimate range again to reflect the better-than-expected performance. The pipeline is delivering late-stage wins, notably with Rinvoq, Epkinly, and Qulipta.
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
AbbVie to launch ovarian cancer drug in UK at the same list price as US
AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S.
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note
The latest trading day saw AbbVie (ABBV) settling at $220.81, representing a +2.1% change from its previous close.
AbbVie shares rise with extension of RINVOQ patent protection to 2037
Abbvie Inc (NYSE:ABBV) shares moved higher after the pharma company announced it has secured extended patent protection for its blockbuster autoimmune drug RINVOQ (upadacitinib). It said in a regulatory filing that it has reached settlements with all generic manufacturers that had filed applications to produce generic versions of RINVOQ, effectively extending US patent protection until April 2037, assuming pediatric exclusivity is granted.
AbbVie in Settlement With Generic Drugmakers on Rinvoq
The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation.
AbbVie: What's Happening With ABBV Stock?
AbbVie's stock is on the rise, and for good reason! The company just reached a major agreement with generic drug manufacturers to delay the release of a generic version of its blockbuster drug, Rinvoq, until 2037.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
AbbVie (ABBV) closed at $210 in the latest trading session, marking a -1.2% move from the prior day.
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
